Piper Sandler raised the firm’s price target on Guardant Health (GH) to $120 from $90 following quarterly results. The firm keeps an Overweight rating on the shares.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GH:
- Guardant Health Completes $402.5M Convertible Notes Offering
- Cathie Wood Buys the Dip in Pinterest (PINS), Sells Roku and Robinhood Stocks
- Guardant Health announces Shield blood-based screening test results
- Guardant Health 3.33M share Spot Secondary priced at $90.00
- Guardant Health announces $250M common stock offering